Media stories about PetIQ (NASDAQ:PETQ) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. PetIQ earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.2573635822718 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
PETQ stock traded up $0.19 on Tuesday, hitting $23.11. The company had a trading volume of 353,982 shares, compared to its average volume of 334,052. PetIQ has a 12-month low of $17.03 and a 12-month high of $28.23. The company has a current ratio of 5.99, a quick ratio of 3.56 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $525.25 and a P/E ratio of 59.56.
PetIQ (NASDAQ:PETQ) last issued its earnings results on Tuesday, March 13th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.14. The company had revenue of $51.93 million during the quarter, compared to analysts’ expectations of $51.63 million. equities analysts predict that PetIQ will post 0.79 earnings per share for the current year.
PETQ has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of PetIQ from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Friday, March 16th. Jefferies Group restated a “buy” rating and issued a $31.00 target price on shares of PetIQ in a report on Wednesday, April 11th. Finally, BidaskClub upgraded shares of PetIQ from a “hold” rating to a “buy” rating in a report on Wednesday, March 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. PetIQ currently has a consensus rating of “Buy” and a consensus price target of $28.17.
In other news, CFO John Newland sold 5,500 shares of PetIQ stock in a transaction on Monday, March 19th. The shares were sold at an average price of $24.83, for a total transaction of $136,565.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Mccord Christensen sold 40,000 shares of PetIQ stock in a transaction on Monday, March 19th. The stock was sold at an average price of $24.92, for a total transaction of $996,800.00. The disclosure for this sale can be found here. Insiders sold 65,500 shares of company stock worth $1,657,765 in the last 90 days.
WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/17/petiq-petq-receives-news-impact-score-of-0-16.html.
PetIQ, Inc is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield.
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.